BV Improves Outcomes in HL
Results from the AETHERA Trial, a phase III, randomised, double-blind, placebo controlled, multicentre study, showed that the addition of brentuximab vedotin (BV) following autologous stem cell transplant (ASCT) resulted in longer progression-free survival (PFS) compared with best supportive care in those with relapsed or refractory Hodgkin lymphoma (HL).
Findings were presented at the 2014 American Society of Hematology annual meeting. Patients (n = 327) were randomised to receive either BV or BSC. At a median follow-up of two years, those receiving BV had a 20% improvement with no disease progression and 88% of patients who received BV were still alive.
Read more here.